Log In Sign up
The largest database of trusted experimental protocols

Anti cd11b pe

Manufactured by Agilent Technologies
Visit Supplier
Sourced in Switzerland

Anti-CD11b-PE is a fluorescently-labeled antibody that binds to the CD11b cell surface antigen. CD11b is expressed on the surface of various immune cells, including monocytes, granulocytes, and natural killer cells. The PE (Phycoerythrin) fluorescent label allows for the detection and quantification of CD11b-positive cells using flow cytometry or other fluorescence-based analytical techniques.

Automatically generated - may contain errors

Lab products found in correlation

P 4e bp1 thr37 46, by Cell Signaling Technology (2 mentions) Anti p mtor ser2448, by Cell Signaling Technology (2 mentions) Anti ulk1, by Cell Signaling Technology (2 mentions) Anti atg13, by Cell Signaling Technology (2 mentions) Anti lc3b wb nb600 1384, by Novus Biologicals (2 mentions) Anti lamp1, by Thermo Fisher Scientific (2 mentions) Anti p62 hpa003196, by Merck Group (2 mentions) Anti yh2ax, by Cell Signaling Technology (2 mentions) Anti tfeb, by Cell Signaling Technology (2 mentions) Anti fasn, by Cell Signaling Technology (2 mentions) Anti α tubulin, by Cell Signaling Technology (2 mentions) Anti cleaved parp, by Cell Signaling Technology (2 mentions) Anti p ulk1, by Cell Signaling Technology (1 mentions) Anti pten, by Cell Signaling Technology (1 mentions) Anti p akt ser473, by Cell Signaling Technology (1 mentions)

Close spelling variants of this product

CD11b (3 citations) Anti-TM (1 citations)

2 protocols using anti cd11b pe

1

Comprehensive Antibody-based Proteomics Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies used were anti-FASN (3180; Cell Signaling, Switzerland), anti-LC3B (WB: NB600-1384, Novus biological, Switzerland; IF: 3868; Cell Signaling, Switzerland) anti-LAMP1 (14-1079-80; Thermofisher, Switzerland), anti-p62 (HPA003196; Sigma-Aldrich, Switzerland), anti-TFEB (4240; Cell Signaling, Switzerland), anti-p-TFEB (Ser 211) (37681S, Cell Signaling, Switzerland), anti-p-AKT (Ser473) (4060S, Cell Signaling, Switzerland) anti-PTEN (9552, Cell Signaling, Switzerland), anti-ULK1 (4776; Cell Signaling, Switzerland), anti-p-ULK1 (Ser757, equivalent to Ser758 of human ULK1) (6888; Cell Signaling, Switzerland), anti-ATG13 (6940; Cell Signaling, Switzerland), anti-pATG13 (Ser318) (600-401-C49; Rockland, Switzerland), anti p-mTOR (Ser2448) (5536; Cell Signaling, Switzerland), p4E-BP1 (Thr37/46) (2855; Cell Signaling, Switzerland), anti-α-tubulin (3873; Cell Signaling, Switzerland), anti-cleaved PARP (9541; Cell Signaling, Switzerland), anti yH2AX (2577; Cell Signaling, Switzerland) and anti-CD11b-PE (R0841; Dako, Switzerland).
Humbert M., Seiler K., Mosimann S., Rentsch V., Sharma K., Pandey A.V., McKenna S.L, & Tschan M.P. (2021). Reducing FASN expression sensitizes acute myeloid leukemia cells to differentiation therapy. Cell Death and Differentiation, 28(8), 2465-2481.
+ Open protocol
+ Expand
2

Autophagy Regulatory Pathway Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies used were anti-FASN (3180; Cell Signaling, Switzerland), anti-LC3B (WB: NB600-1384, Novus biological, Switzerland; IF: 3868; Cell Signaling, Switzerland) anti-LAMP1 (14-1079-80; Thermofisher, Switzerland), anti-p62 (HPA003196 ; Sigma-Aldrich, Switzerland), anti-TFEB (4240; Cell Signaling, Switzerland) anti-ULK1(4776; Cell Signaling, Switzerland), anti p-ULK1 (Ser757) (6888; Cell Signaling, Switzerland), anti-ATG13 (6940 ; Cell Signaling, Switzerland), anti-pATG13 (Ser318) (600-401-C49; Rockland, Switzerland), anti p-mTOR (Ser2448) (5536; Cell Signaling, Switzerland), p4E-BP1 (Thr37/46) (2855; Cell Signaling, Switzerland), anti-α-tubulin (3873; Cell Signaling, Switzerland), anti-cleaved PARP (9541; Cell Signaling, Switzerland), anti yH2AX (2577; Cell Signaling, Switzerland) and anti-CD11b-PE (R0841; Dako, Switzerland).
Humbert M., Seiler K., Mosimann S., Rentsch V., Marfè G., & Tschan M.P. (2020). Reducing FASN expression sensitizes acute myeloid leukemia cells to differentiation therapy.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!